Drug Repositioning in Antimicrobial Therapy, 2nd Edition

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1188

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy-Drug Science, University of Bari Aldo Moro, Bari, Italy
Interests: biological active compounds; antimicrobials; antiarrhythmics; anticancers; melatonergic drugs; voltage-gated sodium channel blockers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy-Drug Science, University of Bari Aldo Moro, Bari, Italy
Interests: therapeutic strategy

Special Issue Information

Dear Colleagues,

The first volume of the Special Issue “Drug Repositioning in Antimicrobial Therapy” was published successfully, and this encouraged us to open a second volume focused on the same topic.

As a continuation of the first Special Issue, this second volume will also deliver the latest approaches and challenges associated with the development of drug repositioning. Topics may include, but are not limited to:

  • Drug repositioning;
  • Anti-infective agents;
  • Bacterial resistance;
  • Multi-drug resistant bacteria;
  • Essential oils;
  • Chemotherapy;
  • Antimicrobial therapy.

Dr. Alessia Carocci
Dr. Alexia Barbarossa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1043 KiB  
Article
Antifungal Biofilm Inhibitory Effects of Combinations of Diclofenac and Essential Oils
by Alexia Barbarossa, Antonio Rosato, Antonio Carrieri, Roberta Tardugno, Filomena Corbo, Maria Lisa Clodoveo, Giuseppe Fracchiolla and Alessia Carocci
Antibiotics 2023, 12(12), 1673; https://doi.org/10.3390/antibiotics12121673 - 28 Nov 2023
Viewed by 880
Abstract
Systemic fungal infections have risen in recent decades and most of them are caused by Candida species, which are becoming increasingly resistant to conventional antifungal drugs. Biofilm production has been considered the most common growth form of Candida cells and is associated with [...] Read more.
Systemic fungal infections have risen in recent decades and most of them are caused by Candida species, which are becoming increasingly resistant to conventional antifungal drugs. Biofilm production has been considered the most common growth form of Candida cells and is associated with a high level of antifungal resistance. At present, international research reports on the antifungal activity of non-traditional antimicrobial drugs and their potential use against life-threatening resistant fungal infections. Indeed, drug repurposing has led to the consideration of well-known compounds as a last-line therapy. The goal of this work is to evaluate the potential synergistic antifungal biofilm activity of new combinations between diclofenac sodium salt (DSS), a widely used non-steroidal anti-inflammatory drug (NSAID), with the essential oils (EOs) of Mentha piperita, Pelargonium graveolens, and Melaleuca alternifolia, whose antifungal activity has been well documented over the years. The in vitro antifungal activity of DSS and EOs was determined on different Candida strains. Susceptibility testing and the synergism of DSS and EOs versus biofilm cells was performed by using the broth microdilution assay and checkerboard methods. Minimum inhibitory concentrations (sMIC50) of DSS alone ranged from 1.25 to 2.05 mg/mL for all the strains considered. These values significantly decreased when the drug was used in combination with the EOs. The fractional inhibitory concentration index (FICI) was lower than 0.5 for almost all the associations, thus indicating a significant synergism, particularly for the DSS–Pelargonium graveolens combination towards the Candida strains examined. These preliminary results show that the combination of the EOs with DSS improves the antifungal activity on all the tested Candida strains, significantly lowering the concentrations of the components used and thus allowing any toxic effects to be overcome. Full article
(This article belongs to the Special Issue Drug Repositioning in Antimicrobial Therapy, 2nd Edition)
Show Figures

Figure 1

Back to TopTop